Oath Surgical is collaborating with NVIDIA to advance the artificial intelligence (AI) capabilities of the OathOS platform used in the former’s network of surgery centres across the US.

Nvidia is no longer content to be the chip supplier behind other companies’ biotech ambitions. With a multibillion dollar slate of commitments, the company is moving directly into the heart of AI drug discovery,

Shares of GPU titan Nvidia (NASDAQ:NVDA) may have been stuck in a sideways channel for the past six months, but a lot has been going on behind the scenes amid the intense sideways action. Of course, Nvidia isn’t solely to blame for the recent consolidation.

Artificial intelligence is scrubbing in and entering the OR. The goal is to collect insight and help doctors focus exclusively on care.

The chip giant became a dominant player in startup investing last year. It took part in 14 funding rounds, up from seven in 2024.

The announcements reflect a calculated shift from discrete chip sales to integrated systems that address enterprise infrastructure bottlenecks.

NVIDIA and its partners have, over recent days, unveiled a wave of new AI hardware and collaborations, from Blackwell-based GeForce RTX 5090 gaming cards and Vera Rubin data center systems to deep-life-sciences tie‑ups with Eli Lilly,

Nvidia will start delivering its promising Rubin platform to buyers in the second half of 2026.

Samsung to reportedly make HBM4 official debut at NVIDIA GTC 2026 in March, during its big 'Rubin' AI platform announcement, passing final NVIDIA tests.